A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.

ABSTRACT: Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumorally at 10⁶ PFU/mL on day 1 (cycle 1), 10⁸ PFU/mL on day 22 (cycle 2), and 10⁸ PFU/mL every 2 weeks thereafter (cycles ≥ 3). Nine patients were enrolled, 6 with only locoregional disease and 3 with both locoregional and distant disease. No patient completed the planned 10 cycles or achieved complete or partial response. The median number of cycles administered was 4 (range, 3-8). Seven patients withdrew prematurely because of uncontrolled disease progression, 1 withdrew a

SUBMITTER: Kai M 

PROVIDER: S-EPMC8593093 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature